News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Amgen Gets Priority Review For Prolia
July 19, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pharma Times -- Amgen has received a boost with the news that regulators in the USA have granted a priority review to the company’s recently-approved denosumab, this time for the reduction of skeletal related events in advanced cancer patients.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Regulatory
MORE ON THIS TOPIC
Podcast
Unpacking the Latest MAHA Report, RFK’s Senate Appearance, FDA’s CRL Drop and More
September 10, 2025
·
1 min read
·
Jef Akst
Complete response letters
FDA Turns Away Ultra-Rare Disease Therapy
September 9, 2025
·
2 min read
·
Tristan Manalac
FDA
FDA Demurs on GLP-1 Compounding Fight, Debuts Consumer ‘Green List’ Instead
September 8, 2025
·
2 min read
·
Annalee Armstrong
Lung cancer
Summit’s Keytruda Challenger Hits Cross-Country Consistency Problems, Raising US Approval Questions
September 8, 2025
·
2 min read
·
Tristan Manalac
